Press Releases

SALT LAKE CITY, Sept. 1, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Morgan Stanley Global Healthcare Conference —  September

SALT LAKE CITY, Aug. 18, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned  Institutional Shareholder

Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2 -mutated meningiomas On track to initiate our Phase 2 clinical trial for the potential treatment of FAP in the third quarter of 2022 U.S. FDA granted Recursion Fast Track designation and

SALT LAKE CITY, Aug. 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference: KeyBanc Technology Leadership Forum —  August 8 through

SALT LAKE CITY, July 21, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential

If successful, REC-2282 could be the first approved treatment for  NF2 -mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S.

SALT LAKE CITY, June 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences: Jefferies Healthcare Conference  — June 8 through

Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2 -mutated meningiomas in the second quarter 2022 Received Fast Track Designation for REC-4881, a

SALT LAKE CITY, May 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conference: Bank of America 2022 Healthcare Conference —  May

SALT LAKE CITY, April 11, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for